Coronavirus channel feed

Covid-19 roundup: Trump sug­gests Pfiz­er vac­cine could be first ap­proved; VBI Vac­cines inks de­vel­op­ment deal with Cana­da

5 years ago

As­traZeneca pub­lish­es Covid-19 vac­cine PhI­II pro­to­cols in lock­step with Mod­er­na and Pfiz­er. How are they dif­fer­ent?

5 years ago

A mi­cro-cap with a po­ten­tial­ly promis­ing coro­n­avirus drug en­lists mask-skep­tic con­gress­man for DSMB

5 years ago
People

Pfiz­er match­es Mod­er­na with their full Covid-19 tri­al blue­print — As­traZeneca says it will un­veil its pro­to­col 'short­ly'

5 years ago
R&D

Covid-19 roundup: AlloVir snags IND ap­proval for po­ten­tial T cell ther­a­py; Sanofi and GSK strike 300 mil­lion-dose deal with the EU 

5 years ago

Roche says a sec­ond tri­al of Actem­ra re­vives hopes for IL-6. What now?

5 years ago

Covid-19 roundup: Amid calls for trans­paren­cy, Mod­er­na re­leas­es full PhI­II pro­to­col; As­traZeneca tri­al halt thought to be 'con­firmed trans­verse myelitis,' per CNN

5 years ago

An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

5 years ago
R&D

Covid-19 roundup: Warp Speed re­leas­es vac­cine dis­tri­b­u­tion plans, but leaves key ques­tions unan­swered

5 years ago

NIH ‘very con­cerned’ about se­ri­ous side ef­fect in As­traZeneca's PhI­II Covid-19 tri­al

5 years ago
FDA+

Covid-19 roundup: Ger­many pours near­ly $450M in­to BioN­Tech; As­traZeneca still has­n't re­sumed its vac­cine tri­al in the US

5 years ago

Covid-19 roundup: Eli Lil­ly de­clares suc­cess on JAK block­er in NIH tri­al; UK gives small biotech a big vac­cine deal

5 years ago

Six days af­ter a star­tling tri­al halt, As­traZeneca gets a green light to re­sume dos­ing their Ox­ford Covid-19 vac­cine

5 years ago
R&D

Covid-19 roundup: NIH spot­lights blood thin­ners in its next big tri­al; All it took was a pan­dem­ic to get JPM out of SF

5 years ago

Pas­cal So­ri­ot says 2020 ap­proval still pos­si­ble for As­traZeneca's Covid-19 vac­cine as the world awaits the safe­ty board­'s de­ci­sion

5 years ago

Ex­clu­sive: Gink­go teams with un­known up­start in hunt for Covid-19 an­ti­body

5 years ago
Startups

Covid-19 roundup: Fau­ci re­it­er­ates Oc­to­ber vac­cine OK 'un­like­ly'; Pfiz­er and BioN­Tech re­serve 200M dos­es for EU

5 years ago

An­a­lysts as­sess fall­out af­ter As­traZeneca halts PhI­II Covid-19 vac­cine dos­ing to probe a pos­si­ble se­ri­ous ad­verse event

5 years ago
R&D

Phar­ma's bat­tered rep gets a mod­est facelift in the lat­est in­dus­try rat­ings from Gallup — but it's still look­ing pret­ty bad

5 years ago
Bioregnum
Pharma

Cell­tri­on to be­gin mass pro­duc­ing an­ti­body treat­ment be­fore get­ting ap­proval

5 years ago
R&D

Covid-19 roundup: Af­ter bat­ting back at vac­cine sup­pli­er, In­ovio lines up a gi­ant in its cor­ner; Ox­ford spin­out Spy­Biotech be­gins PhI/II dos­ing for VLP-based vac­cine

5 years ago

CEOs join reg­u­la­tors and top sci­en­tists vow­ing to hold the line on Covid-19 vac­cine. But will that get in the way of Trump's 'big sur­prise'?

5 years ago
Bioregnum
Opinion

Covid-19 roundup: Cure­Vac ex­pands cache to $1.3B as coro­n­avirus race heats up; Russ­ian sci­en­tists pub­lish ear­ly da­ta to back up vac­cine

5 years ago

Mon­cef Slaoui calls late Oc­to­ber vac­cine roll­out 'ex­treme­ly un­like­ly,' vows again to re­sign un­der un­due po­lit­i­cal in­flu­ence

5 years ago
First page Previous page 43444546474849 Next page Last page
A service from the Financial Times